Elanco Animal Health Incorporated Stock Price and Value Analysis

Elanco Animal Health Incorporated (NYSE:ELAN) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Elanco Animal Health Incorporated to reach your target.

Target type

ELAN Free Cash Flow Trend

Free Cash Flow trendline for ELAN
Free Cash Flow trendline for Elanco Animal Health Incorporated
CSV

Based on historical returns, we believe that Elanco Animal Health Incorporated can grow its free cash at a rate of about 1%. That's positive!

AdvantagesDisadvantagesNeutral
None.
  • This company is less known than others.
  • This stock looks overpriced.
  • This company is making money at a modest rate.
  • This company has wild ups and downs.
  • This company pays no dividend.

Inside the ELAN Numbers

ELAN Price
(Elanco Animal Health Incorporated stock price per share)
$25.74
[?] ELAN Fair Price
(based on intrinsic value)
$13.10
[?] ELAN Safety Price (based on a variable margin of safety) $7.86
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 365% higher than other Healthcare stocks
[?] PE Ratio versus Industry 0% lower than other Drug Manufacturers - General stocks
[?] Free Cash Flow Jitter 79%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 32,923,699 shares shorted. With 495,703,494 shares available for purchase and an average trading volume over the past 10 trading days of 5,890,450, it would take at least 5.6 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2016 1739104 45.6
2017 1739104 69.3
2018 1739104 373
2019 1739104 103
2020 1739104 -165
2021 1739104 350
2022 1739104 304
2023 1739104 122
2024 1739104 391
2025 1739104 381

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 3 fiscal years from 2016 to 2025 with positive net income, operating cash flow totaled $1,252 million against net income of $493 million, or 2.54 times. Net income was negative in 7 of the 10 years, and those years are left out of the ratio.

In 2025, net income was -$232 million and operating cash flow was $560 million, so no ratio is shown for that year.

In 2025, capital expenditures were $276 million, 49.3% of operating cash flow of $560 million, which leaves an estimated $284 million after capex. Across the 9 years with reported capex, it averaged 41.1% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2016 -47.9 156 110 n/a
2017 -311 174 98.6 n/a
2018 86.5 487 135 5.63
2019 68 224 140 3.29
2020 -574 -41 135 n/a
2021 -483 483 159 n/a
2022 -78 452 171 n/a
2023 -1,231 271 140 n/a
2024 338 541 147 1.60
2025 -232 560 276 n/a

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $2,914 million in 2016 and $4,715 million in 2025, a compound annual growth rate of 5.5% over 9 years.

Revenue rose 6.2% from 2024 to 2025.

Our estimated free cash flow was $381 million in 2025, 8.1% of revenue. In 2016 the estimated margin was 1.6%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2016 2,914 45.6 1.6%
2017 2,889 69.3 2.4%
2018 3,067 373 12.2%
2019 3,071 103 3.4%
2020 3,273 -165 -5.0%
2021 4,764 350 7.3%
2022 4,411 304 6.9%
2023 4,417 122 2.8%
2024 4,439 391 8.8%
2025 4,715 381 8.1%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $545 million against total liabilities of $6,811 million, or 8.0% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 51.0% of total assets in 2025, compared with 13.0% in 2017, an increase of 38.0 percentage points.

Stockholders equity was $6,547 million in 2025, compared with $7,780 million in 2017, a fall of 15.9%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 3.4% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2017 8,940 323 1,160 7,780
2018 8,957 475 3,760 5,197
2019 8,986 334 3,443 5,543
2020 17,693 495 9,236 8,457
2021 16,478 638 8,970 7,508
2022 15,491 345 8,202 7,289
2023 14,362 352 8,139 6,223
2024 12,614 468 6,518 6,096
2025 13,358 545 6,811 6,547

Price Versus Our Estimated Value

Positive free cash flow appears in 9 of the 10 fiscal years we hold for Elanco Animal Health Incorporated from its current SEC filer.

Our fair value estimate for Elanco Animal Health Incorporated is $13.10, below its current price of $25.74.

Free cash flow from the first three years of data averaged $163 million, and from the last three $298 million: a sharp rise.

Free cash flow is volatile from year to year, with a variability measure of 79%.

Dividends are not in our data for Elanco Animal Health Incorporated.

Before you act on any of this, read what a margin of safety means and check the company's own filings.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 365% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is in line with the average for stocks in the Drug Manufacturers - General industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to Elanco Animal Health Incorporated, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Elanco Animal Health Incorporated (ELAN) 12,866 - - - 96% above
Jazz Pharmaceuticals plc (JAZZ) 14,780 68.1 - 3.4% 53% below
Alkermes plc (ALKS) 7,552 - - 1.5% 315% above
Corcept Therapeutics Incorporated (CORT) 7,112 48.9 - 0.0% 858% above
Viatris (VTRS) 22,505 - 2.4% - 2% below
Prestige Consumer Healthcare (PBH) 2,352 15.3 - 7.8% 50% below
Perrigo Company plc (PRGO) 2,213 - 7.2% 72.9% 91% below

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1739104.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 1 of the 10 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-21
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: ELAN annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in ELAN

Does Elanco Animal Health Incorporated have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: ELAN

This example shows how we apply the Trendshare checklist to ELAN: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 25.74
    • Market cap: $13B
    • EPS: -0.3
  2. Step 2 — Valuation checks

    • P/E: —
    • FCF yield: —
    • Date checked: Nov 21, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.